Medical Treatment of Hepatocellular Carcinoma
2009

Medical Treatment of Hepatocellular Carcinoma

publication Evidence: moderate

Author Information

Author(s): Alessandro Granito, Luigi Bolondi

Primary Institution: Policlinico S. Orsola Malpighi, Bologna, Italy

Conclusion

New therapies, including sorafenib, have shown survival benefits for patients with advanced hepatocellular carcinoma.

Supporting Evidence

  • Hepatocellular carcinoma is the fifth most common cancer and a leading cause of cancer-related deaths.
  • Surveillance programs for high-risk populations can improve early detection and treatment outcomes.
  • Sorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma.

Takeaway

Hepatocellular carcinoma is a serious liver cancer, but there are treatments that can help people live longer, especially if caught early.

Methodology

The article reviews various treatment options for hepatocellular carcinoma, including surgical and non-surgical methods.

Limitations

The study does not provide definitive data on all treatment options and their effectiveness across different patient demographics.

Participant Demographics

The article discusses various demographics affected by hepatocellular carcinoma, including those with chronic hepatitis B and C.

Statistical Information

P-Value

p=0.005

Confidence Interval

95% CI 0.55–0.87

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4084/MJHID.2009.021

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication